New pill tested to control advanced breast cancer
NCT ID NCT03284957
Summary
This study tested a new oral drug called amcenestrant for postmenopausal women with advanced, estrogen receptor-positive breast cancer. The main goals were to find safe doses and see if the drug, given alone or with other cancer therapies, could help control the disease. The trial was terminated early and enrolled 136 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutchinson Cancer Center- Site Number : 8400001
Seattle, Washington, 98109, United States
-
Investigational Site Number : 0560001
Leuven, 3000, Belgium
-
Investigational Site Number : 1240002
Toronto, Ontario, M4N 3M5, Canada
-
Investigational Site Number : 1240003
Vancouver, British Columbia, V5Z 1L3, Canada
-
Investigational Site Number : 1240004
Edmonton, Alberta, T6G 1Z2, Canada
-
Investigational Site Number : 2030001
Prague, 128 08, Czechia
-
Investigational Site Number : 2030002
Brno, 656 53, Czechia
-
Investigational Site Number : 2030003
Prague, 140 59, Czechia
-
Investigational Site Number : 2500001
Saint-Herblain, 44805, France
-
Investigational Site Number : 2500002
Bordeaux, 33076, France
-
Investigational Site Number : 2500003
Lyon, 69373, France
-
Investigational Site Number : 2500004
Villejuif, 94805, France
-
Investigational Site Number : 2500005
Lille, 59000, France
-
Investigational Site Number : 3800003
Milan, Milano, 20141, Italy
-
Investigational Site Number : 6160004
Gdynia, Pomeranian Voivodeship, 81-519, Poland
-
Investigational Site Number : 6200001
Lisbon, 1649-035, Portugal
-
Investigational Site Number : 6200002
Lisbon, 1998-018, Portugal
-
Investigational Site Number : 7240001
Madrid, 28041, Spain
-
Investigational Site Number : 7240002
Madrid, 28050, Spain
-
Investigational Site Number : 7240007
Madrid, 28034, Spain
-
Investigational Site Number : 8260002
Cardiff, Cardiff [Caerdydd Gb-crd], CF14 2TL, United Kingdom
-
Investigational Site Number : 8260003
Oxford, Oxfordshire, OX3 7LE, United Kingdom
-
Massachusetts General Hospital- Site Number : 8400002
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center - New York - York Avenue- Site Number : 8400003
New York, New York, 10065, United States
-
University of Colorado - Anschutz Medical Campus- Site Number : 8400005
Aurora, Colorado, 80045, United States
Conditions
Explore the condition pages connected to this study.